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Resveratrol, an important phytoalexin in many plants, has been
reported to have cytotoxic effects on various types of cancer. Ce-
ramide is a bioactive sphingolipid that regulates many signal-
ing pathways, including cell growth and proliferation, senescence
and quiescence, apoptosis, and cell cycle. Ceramides are gener-
ated by longevity assurance genes (LASS). Glucosylceramide syn-
thase (GCS) and sphingosine kinase-1 (SK-1) enzymes can con-
vert ceramides to antiapoptotic molecules, glucosylceramide, and
sphingosine-1-phosphate, respectively. C8:ceramide, an important
cell-permeable analogue of natural ceramides, increases intracellu-
lar ceramide levels significantly, while 1-phenyl-2-decanoylamino-
3-morpholino-1-propanol (PDMP) and SK-1 inhibitor increase ac-
cumulation of ceramides by inhibiting GCS and SK-1, respectively.
Chronic myelogenous leukemia (CML) is a hematological disorder
resulting from generation of BCR/ABL oncogene. In this study, we
examined the roles of ceramide metabolizing genes in resveratrol-
induced apoptosis in K562 CML cells. There were synergistic cyto-
toxic and apoptotic effects of resveratrol with coadministration of
C8:ceramide, PDMP, and SK-1 inhibitor. Interestingly, there were
also significant increases in expression levels of LASS genes and
decreases in expression levels of GCS and SK-1 in K562 cells in
response to resveratrol. Our data, in total, showed for the first time
that resveratrol might kill CML cells through increasing intracel-
lular generation and accumulation of apoptotic ceramides.
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INTRODUCTION
Resveratrol (3,5,4′-trans-trihydroxystilbene) is a natural
product generated in various plants, especially in the skin and
seeds of red grapes, to protect them in stress conditions, such
as fungal infections or UV irradiation (1,2). Resveratrol has
drawn increasingly more attention recently since it has antiin-
flammatory, antimetastatic, cardioprotective, chemopreventive,
cancer-preventive, apoptosis inducer, and radio-sensitizer po-
tentials (3–5). Resveratrol affects the processes of tumor initia-
tion, promotion, and progression (6). It is very well known that
resveratrol can bind directly to DNA and RNA. Therefore, it can
protect DNA from genotoxic effects of mutagens. On the other
hand, resveratrol can also inhibit DNA topoisomerase II enzyme
and induce apoptosis (6). Different mechanisms were explained
for resveratrol-induced apoptosis, such as repression of NF-κB
and STAT3 pathways and downregulation of cyclin D1, Bcl-2,
Bcl-XL, XIAP, and AKT genes (7). We have previously showed
the antiproliferative effect of resveratrol on cultured chronic
myeloid leukemia (CML) cells (1). CML is a clonal hematolog-
ical disorder, which raises from reciprocal translocation between
the BCR (break point cluster) gene on chromosome 22 and the
ABL (Abelson leukemia virus oncogene) gene on chromosome
9, t(9,22)(q34,q11), resulting in the formation of BCR/ABL fu-
sion protein (8). This fusion protein possesses constitutive tyro-
sine kinase activity (9). Furthermore, BCR/ABL induces several
signal transduction pathways that mediate cellular proliferation
and cause the disruption of the genetic maintenance. Although
there are very effective treatment agents targeting BCR/ABL
oncogene, emergence of the resistance is a significant prob-
lem for the treatment of CML. However, the roles of bioactive
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sphingolipids in resveratrol-induced apoptosis in cultured CML
cells have not been examined previously.
Ceramide, the most important bioactive sphingolipid, con-
stitutes a signaling mediator of various biological activities, in-
cluding cell cycle arrest, cell senescence, cell migration and ad-
hesion, differentiation, and apoptosis in various types of normal
and tumor cells (10). It has been shown that intracellular concen-
trations of ceramides are increased in response to chemother-
apy, ionizing radiation and several environmental stress condi-
tions (11). Ceramide levels are regulated by longevity assurance
genes (LASS) that synthesize ceramides and by glucosylece-
ramide synthase (GCS) and sphingosine kinase-1 (SK-1) that
convert apoptotic ceramides to antiapoptotic glucosylceramide
and sphingosine-1-phosphate (S1P), respectively (12). Unlike
ceramides, increasing concentrations of glucosylceramide and
S1P in the cell promote cell growth and proliferation (12). In
addition, it has been reported that elevated levels of GCS and
S1P cause multidrug resistance in many cancer cells (12–14).
We have previously shown that ceramides have significant roles
in the sensitivity and resistance of CML cells to imatinib (10).
In addition, there are some other studies showing the effects
of resveratrol on ceramide generation. Ersilia Dolfini et al. have
shown that resveratrol may prevent the growth of MDA-MB-231
breast cancer cells through inducing de novo ceramide gener-
ation (15). In another study, it was also shown that resveratrol
triggers autophagy in gastric cancer cells via increasing intra-
cellular ceramide levels (16).
We and some others have reported that targeting ceramide
metabolism induces apoptotic signaling pathways and, there-
fore, promotes apoptosis in various types of cancer, including
CML (10,17). In this study, our hypothesis was that ceramide
generating and ceramide clearance genes may be involved
in resveratrol-induced apoptosis. We also hypothesized that
targeting bioactive sphingolipid metabolism by mimetics/
inhibitors that trigger ceramide generation and accumulation
can increase apoptotic effects of resveratrol on K562 CML
cells.
MATERIALS AND METHODS
Cell Line and Chemicals
Human K562 CML cells were obtained from German Collec-
tion of Microorganisms and Cell Cultures (Germany). Resvera-
trol (trans-3,4′, 5-trihydroxystilbene) was obtained from Sigma
Aldrich (St. Louis, MO). The stock solution of resveratrol
was dissolved in dimethylsulfoxide (DMSO) at a concentra-
tion of 10 mmol/mL, stored at −20◦C, and diluted in cell
culture medium. C8:ceramide, 1-phenyl-2-decanoylamino-3-
morpholino-1-propanol (PDMP), and SK-1 inhibitor were ob-
tained from Cayman Chemicals (Ann Arbor, MI) and dissolved
in DMSO. Penicillin-streptomycin, RPMI1640, and fetal bovine
serum were obtained from Invitrogen (Paisley, UK).
Culture Conditions
The Ph (+) human K562 CML cells were cultured in
RPMI1640 growth medium containing 10% fetal bovine serum
and 1% penicillin-streptomycin at 37◦C in 5% CO2.
Measurement of Cell Growth by XTT Assay
The IC50 values (drug concentration that inhibits cell growth
by 50%) of resveratrol and C8:ceramide, and the IC10 val-
ues (drug concentration that inhibits cell growth by 10%) of
PDMP and SK-1 inhibitor were determined by XTT cell pro-
liferation assay. In short, 2 × 104 cells/well were seeded into
96-well plates containing 100 µl of the growth medium in the
absence or presence of increasing concentrations of resvera-
trol, C8:ceramide, PDMP, or SK-1 inhibitor and then incubated
at 37◦C in 5% CO2. After 72 h incubation period, cells were
treated with 50 µl XTT for 4 h. Then, the plates were read
under 492-nm wavelengths by ELISA reader (Thermo Elec-
tron Corporation Multiskan Spectrum, Vantaa, Finland). Finally,
IC50 values of resveratrol and C8:ceramide, and IC10 values of
PDMP and SK-1 inhibitor were calculated from the cell prolif-
eration plots. We prefer to combine increasing concentrations of
resveratrol with IC10 values of PDMP and SK-1 inhibitor since
we have shown previously that IC10 values of these chemicals
are enough to inhibit the enzyme activity and provide accumu-
lation of ceramides in the cells (10). On the other hand, since
C8:ceramide by itself triggers induction of generation of apop-
totic ceramide, it can be accepted like a pro-drug. Therefore,
we combined the IC50 value of C8:ceramide with increasing
concentrations of resveratrol. Our main purpose in these com-
binations was to see if we could enhance the sensitivity of K562
cells to resveratrol by increasing intracellular concentrations of
ceramides.
In order to determine the possible synergistic effects of
resveratrol in combination with C8:ceramide, PDMP, or SK-
1 inhibitor, 2 × 104 K562 cells were seeded into each well of
a 96-well plate containing 100 µl of the growth medium. Then
IC50 value of C8:ceramide or IC10 value of PDMP or SK-1 in-
hibitor were applied onto the cells, and the plates were incubated
at 37◦C in 5% CO2 for 18 h. This time period provides increased
generation of ceramides through its induction by C8:ceramide
or increased accumulation of ceramides through inhibition of
conversion of ceramides to glucosylceramide or sphingosine-1-
phosphate by PDMP or SK-1 inhibitor, respectively. Increasing
concentrations of resveratrol were then applied into these plates,
and they were incubated at 37◦C in 5% CO2. After 72 h incu-
bation, cells were treated with 50 µl of XTT mixture for 4 h
and the plates were read under 492 nm wavelengths by ELISA
reader (Thermo Electron Corporation Multiskan Spectrum,
Vantaa, Finland).
Evaluation of Apoptosis
Changes in caspase-3 enzyme activity of the cells, an impor-
tant sign of apoptosis, were examined by caspase-3 colorimetric
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assay kit (BioVision Research Products, Mountain View, CA).
This assay is based on spectrophotometric detection of the
chromophore p-nitroanilide (pNA) after cleavage from the la-
beled substrate DEVD-pNA that can be recognized by caspases.
In short, the cells (1 × 106 cells/2 mL/well), induced to undergo
apoptosis, were collected by centrifugation at 1,000 rpm for 10
min. The cells were lysed by adding 50 µl of chilled cell lysis
buffer and incubated on ice for 10 min before centrifugation at
10,000 g for 1 min. Supernatants were transferred to new Ep-
pendorf tubes, and the reaction mixture was prepared in 96-well
plates by adding 50 µl of 2× reaction buffer (containing 10 mM
DTT), 50 µl of sample, and 5 µl of DEVD-pNA substrate and
incubated for 2 h at 37◦C in a CO2 incubator. At the end of
this period, the plate was read under 405 nm wavelengths by
ELISA reader (Thermo Electron Corporation Multiskan Spec-
trum, Vantaa, Finland). The absorbance values are normalized
to protein concentrations determined by Bradford assay as de-
scribed previously (10).
We have also examined the loss of mitochondrial membrane
potential (MMP), another important sign of apoptosis, in re-
sponse to resveratrol, C8:ceramide, PDMP, and SK-1 inhibitor
or combinations of resveratrol with the others in K562 cells
by the APO LOGIX JC-1 Mitochondrial Membrane Potential
Detection Kit (Cell Technology, Mountain View, CA). This kit
uses JC-1, a unique cationic dye, to signal the loss of the MMP.
JC-1 accumulates in the mitochondria, which stains red in non-
apoptotic cells, while in apoptotic cells, the MMP collapses
and thus the JC-1 remains in the cytoplasm as a monomer that
stains green under fluorescent light. Briefly, the cells (1 × 106
cells/2 mL), induced to undergo apoptosis, were collected by
centrifugation at 1,000 rpm for 10 min. Supernatants were re-
moved, 500 µl of JC-1 dye was added onto the pellets, and
the cells were incubated at 37◦C in 5% CO2 for 15 min. Then,
they were centrifuged at 1,000 rpm for 5 min, and 2 mL of
assay buffer was added onto the pellets. After centrifugation at
1,000 rpm for 5 min, all pellets were resuspended with 500 µl
assay buffer and 150 µl from each of them was added into the
96-well plate. The aggregate red form has absorption/emission
maxima of 585/590 nm, and the monomeric green form has ab-
sorption/emission maxima of 510/527 nm. The plate was read
in these wavelengths by fluorescence ELISA reader (Thermo
Varioskan Spectrum, Vantaa, Finland). At the end, green/red
(510/585) values were calculated to determine the changes in
MMP.
In addition, K562 cells were treated with increasing con-
centrations of resveratrol in combinations with C8:ceramide,
PDMP, or SK-1 inhibitor. For this purpose, K562 cells (1 × 106
cells/2 mL) were seeded into 6-well plates and then treated with
IC50 value of C8:ceramide or IC10 values of PDMP or SK-1 in-
hibitor. After incubating the plates for 18 h at 37◦C in 5% CO2,
increasing concentrations of resveratrol were applied into these
plates. After 72-h incubation, the assay procedure mentioned
above was executed.
Total RNA Isolation and RT-PCR
Total RNAs of K562 cells, treated with increasing doses of
resveratrol, were extracted using a Ribolock RNA isolation kit
(Macherey-Nagel, Du¨ren, Germany) as described by the man-
ufacturer. One µg of each total RNA was reverse transcribed
using reverse transcriptase (Moroney Murine Leukemia Virus
Reverse Transcriptase, Fermentas, Glenburnie, MD). After 50
min of incubation at 42◦C, the reactions were stopped at 95◦C
for 5 min. The resulting total cDNAs were then used in PCR to
measure the mRNA levels of LASS2, LASS4, LASS5, LASS6,
SK1, GCS, and β-actin. The mRNA levels of β-actin were used
as internal positive control. The primer sequences and PCR
conditions were as follows: LASS2-F (5′-GCTGGAGATTCAC
ATTTTAC-3′), LASS2-R (5′-GAAGACGATGAAGATGTT
GT-3′), LASS4-F (5′-TGCTGTCCAGTTTCAACGAG-3′),
LASS4-R (GAGGAAGTGTTTCTCCAGCG-3′), LASS5-F (5′-
TCCTCAATGGCCTGCTGCTG-3′), LASS5-R (5′-CCCGGC
AATGAAACTCACGC-3′), LASS6-F (5′-CTCCCGCACAA
TGTCACCTG-3′), LASS6-R (5′-TGGCTTCTCCTGATTG
CGTC-3′), SK1-F (5′-CCGACGAGGACTTTGTGCTAAT-3′),
SK1-R (5′-GCCTGTCCCCCCAAAGCATAAC-3′), GCS-F
(5′-ATGACAGAAAAAGTAGGCT-3′), GCS-R (5′-GGACA
CCCCTGAGTGGAA-3′), β-actin-F (5′-CAGAGCAAGAGA
GGCATCCT-3′), and β-actin-R (5′-TTGAAGGTCTCAAA
CATGAT-3′). Two µl of the reverse transcriptase reaction prod-
uct was amplified using these primers by PCR for 35 cycles,
and their levels were normalized to that of β-actin as described
previously (10).
After running the PCR products on agarose gel electrophore-
sis, quantification of expression levels of the genes were per-
formed by Quantity One-1D-Gel-Imaging program (Biorad,
Hercules, CA). The results were normalized to β-actin levels.
RESULTS
Resveratrol, C8:ceramide, PDMP, or SK-1 Inhibitor
Showed a Dose-Dependent Cytotoxicity on Human K562
Chronic Myeloid Leukemia Cells
To assess antiproliferative effects of resveratrol,
C8:ceramide, PDMP, or SK-1 inhibitor on human K562
cells, the cells were incubated with increasing concentrations
of the agents for 72 h and XTT cell proliferation assay was
conducted. The aim of application of C8:ceramide, PDMP, and
SK-1 inhibitor is to see whether induction of generation or
accumulation of ceramides inhibit proliferation of K562 cells.
The results showed that there were dose-dependent decreases
in cell proliferation in response to these chemicals as compared
to untreated controls. IC50 values of resveratrol (Fig. 1A) and
C8:ceramide (Fig. 1B) were calculated from cell proliferation
plots and were found to be 80 and 60 µM, respectively, while
IC10 values of PDMP (Fig. 1C) and SK-1 inhibitor (Fig. 1D)
were 20 and 7 µM, respectively.
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FIG. 1. Cytotoxic effects of resveratrol (A), C8:ceramide (B), PDMP (C), and SK-1 Inhibitor (D) on K562 cells. The IC50 concentration of resveratrol,
C8:ceramide, and PDMP and IC10 value of SK-1 inhibitor were calculated from cell proliferation plots. The XTT assays were performed using triplicate samples
in at least 3 independent experiments. The error bars represent the standard deviations.
Synergistic Cytotoxic Effects of Combinations
of Resveratrol With C8:ceramide, PDMP, or SK-1
Inhibitor on K562 Cells
In order to examine the possible synergistic cytotoxic ef-
fects, the cells were exposed to increasing concentrations of
resveratrol from 1 to 100 µM, together with 60 µM
C8:ceramide, 20 µM PDMP, or 7 µM SK-1 inhibitor. The main
FIG. 2. Synergistic cytotoxic effects coadministration of resveratrol with
C8:ceramide or PDMP or SK-1 inhibitor on K562 cells. Cytotoxicity was de-
termined by the XTT cell proliferation assay in a 72-h culture. The XTT assays
were performed using triplicate samples in at least 3 independent experiments.
The error bars represent the standard deviation.
purpose of these combinations was to examine if increasing in-
tracellular concentrations of ceramides increases antiprolifera-
tive effects of resveratrol on K562 cells. Combination of 1-, 50-,
and 100 µM of resveratrol with 60 µM C8:ceramide decreased
proliferation of K562 cells to 87%, 88%, and 89%, respectively,
while resveratrol application alone decreased cell proliferation
8%, 43%, and 59%, respectively (Fig. 2). The same doses of
resveratrol in combination with 20 µM PDMP or 7 µM SK-1 in-
hibitor decreased cell proliferation 29%, 55%, and 68%, or 23%,
54%, and 73%, respectively (Fig. 2). The data demonstrate that
increasing intracellular concentrations of ceramides increased
the antiproliferative effects of resveratrol significantly. The most
significant effect was observed in combination of C8:ceramide
and resveratrol.
Resveratrol Together With C8:ceramide, PDMP, or SK-1
Inhibitor Induces Apoptosis Synergistically in K562 Cells
In order to see apoptotic effects of resveratrol and increased
concentrations of ceramides by ceramide mimetics/inhibitors,
we treated cells with different concentrations of resveratrol,
C8:ceramide, PDMP, and SK-1 inhibitor alone and exam-
ined the changes in caspase-3 enzyme activity and loss of
MMP. In this part of the study, we also investigated if in-
creasing intracellular concentrations of ceramides increases
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FIG. 3. Changes in caspase-3 enzyme activity in response to coadministration of resveratrol with C8:ceramide or PDMP or SK-1 inhibitor. The results are the
means of 3 independent experiments. The error bars represent the standard deviations, and, when not seen, they are smaller than the thickness of the lines on the
graphs.
FIG. 4. Changes in cytoplasmic/mitochondrial JC-1 in K562 cells exposed to combinations of resveratrol with C8:ceramide or PDMP or SK-1 inhibitor. The
results are the means of 3 independent experiments. The error bars represent the standard deviations, and, when not seen, they are smaller than the thickness of the
lines on the graphs.
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apoptotic effects of resveratrol. As shown in Fig. 3, there
were 1.12- and 1.21-fold increases in caspase-3 enzyme
activity in response to 1 and 10 µM resveratrol, respectively.
Coadministration of 60 µM C8:ceramide or 20 µM PDMP or 7
µM SK-1 inhibitor with the same doses of resveratrol increased
caspase-3 enzyme activity 2.11-, and 3.1- or 1.29-, and 1.87-
or 2.36- and 2.49-fold, respectively. The same concentrations
of C8:ceramide, PDMP and SK-1 inhibitor alone caused 1.44-,
1.22-, and 1.83-fold increases in enzyme activity, respectively.
In order to confirm caspase-3 enzyme activity results and
examine the roles of mitochondria in resveratrol-induced apop-
tosis, we also determined the loss of mitochondrial membrane
potential. The results were in agreement with our previous
data and have shown that all these chemicals induce apopto-
sis through induction of loss of MMP. Combination of resvera-
trol with C8:ceramide, PDMP, or SK-1 inhibitor caused loss of
MMP synergistically as compared to any agent alone and any
untreated control group (Fig. 4).
Increased LASS Genes Expression and Decreased SK-1
and GCS Genes Expression Induced by Resveratrol in
K562 Cells
In order to determine whether ceramide metabolizing genes
are involved in resveratrol-induced apoptosis, K562 cells were
treated with increasing concentrations of resveratrol (1, 10, 20,
and 50 µM) and expression levels of LASS2, LASS4, LASS5,
LASS6, GCS, SK-1, and ß-actin were determined by RT-PCR.
As shown in Fig. 5 and Table 1, resveratrol inhibited expression
levels of GCS and, more significantly, of SK-1 genes. On the
contrary, expression levels of LASS2, LASS5, and to a lesser
extent LASS4 and LASS6 were increased in response to resvera-
trol as compared to untreated controls and normalized to ß-actin
levels (see Fig. 5 and Table 1).
DISCUSSION
The incidence of cancer is increasing dramatically, and the
drugs used in cancer therapy are very expensive and have many
side effects. That fact opens the door to investigate novel an-
ticancer agents originated from natural products. Resveratrol
has been reported to have cytotoxic effects on various types of
cancers (1). On the other hand, resveratrol has been shown to
be apoptotic, autophagocytic, a radiotherapy-sensitizer, a cell
cycle arrester, an inhibitor of ROS generation in mitochondria,
and a regulator of p53 in many cancers (4,5,7,18–20). One of
the most important properties of resveratrol is that it has selec-
tive toxic effects on cancer cells and far less effect on normal,
healthy cells (21). However, the roles of bioactive sphingolipids
in resveratrol-induced apoptosis and the effects of resveratrol on
ceramide metabolizing genes have never before been examined
in cultured chronic myeloid leukemia.
In this study, we examined potential cytotoxic and apop-
totic effects of resveratrol and C8:ceramide, an important cell-
permeable analogue of natural ceramides (22), which increases
FIG. 5. Expression levels of LASS2, LASS4, LASS5, LASS6, GCS, SK-1,
and β-actin genes in response to resveratrol in K562 cells. One-, 10-, 20-, and
50 µM resveratrol were applied to K562 cells for 72 h and expression levels of
ceramide metabolizing genes were determined by RT-PCR. Expression levels
of β-actin was detected as an internal positive control.
intracellular ceramide levels significantly, GCS and SK-1 in-
hibitors, which increase accumulation of ceramides on K562
cells. We treated K562 cells with increasing concentrations of
these chemicals and determined their cytotoxic effects by XTT
cell proliferation assay. Our results showed a dose-dependent
decrease in cell proliferation in response to resveratrol and in
response to increased intracellular concentrations of ceramides.
Apoptosis in K562 cells exposed to increasing concentrations
of these chemical agents was also evaluated by examining
the changes in caspase-3 enzyme activity and the loss of the
mitochondrial membrane potential. The results revealed that
resveratrol, C8:ceramide, PDMP, and SK-1 inhibitor might in-
duce apoptosis through increasing caspase-3 enzyme activity
and loss of mitochondrial membrane potential. Increasing intra-
cellular concentrations of ceramides by C8:ceramide was sug-
gested to be an effective approach to inhibit cancer cell growth
(23). Downregulation of GCS and SK-1 by biochemical and/or
molecular techniques are novel effective treatment protocols to
regulate cancer cell growth (24–26).
We then assessed combinational treatments of resvera-
trol with C8:ceramide, the inducer of de novo generation of
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TABLE 1
Quantitative analyses of expression levels of GCS, SK-1, LASS2, LASS4, LASS5, and LASS6 genes in response to resveratrol
Resveratrol-Inhibited
Expression Levels GCS SK-1 LASS2 LASS4 LASS5 LASS6
Control 100 100 100 100 100 100
1 µM Res 83 69 91 101 73 105
10 µM Res 82 41 174 102 57 109
20 µM Res 92 43 182 121 77 129
50 µM Res 83 35 191 121 188 131
apoptotic ceramides, PDMP, the inhibitor of GCS, and SK-
1 inhibitor. When we coadministrate the constant concentra-
tions of C8:ceramide (60 µM), PDMP (20 µM), or SK-1 in-
hibitor (7 µM) with increasing concentrations of resveratrol (1
to 100 µM), synergistic antiproliferative effects were observed
as compared to any agent alone and untreated controls. Ten
µM resveratrol by itself could repress only 18% of cell prolif-
eration, while the same concentration of resveratrol, together
with C8:ceramide, PDMP, or SK-1 inhibitor, inhibited 87%,
46%, and 42% of cell proliferation, respectively (Fig. 2). The
synergistic apoptotic effects of resveratrol in combination with
C8:ceramide, PDMP, or SK-1 inhibitor were also observed by
the changes in caspase-3 enzyme activity and loss of mitochon-
drial membrane potential. As we increased the intracellular con-
centrations of ceramides by application of exogenous ceramide
or by inhibition of the conversion of ceramides to glucosyl-
ceramide or sphingosine-1-phosphate, the sensitivity of K562
cells to resveratrol increased synergistically. Our results were
in agreement with the literature since it was clearly shown that
both caspases and mitochondrial membrane potential are well-
known downstream targets of ceramides (12).
By our group and some other groups it was reported that
resveratrol application results in increases in endogenous ce-
ramide concentrations in prostate, breast (27), and colorectal
carcinoma (2) and acute promyelocytic leukemia cells (28). In-
creases in intracellular concentrations of ceramides were shown
by expression levels of the LASS gene family, GCS and SK-
1 genes, and direct detection of ceramides by LC-MS. There
are 6 genes in the LASS gene family that regulate de novo
ceramide synthesis (29). Mammalian ceramides exist in vari-
ous lengths with their different fatty acids, and each member
of the LASS gene family is responsible for the generation of
these different types of ceramides with different lengths (30).
For instance, LASS1 gene is responsible for the synthesis of
C18:ceramide (31), whereas LASS2 gene is responsible for the
synthesis of C24:ceramide (32), and LASS4 gene is responsible
for the synthesis of C22:ceramide (33). However, LASS5 and
LASS6 genes are responsible for the synthesis of C14:ceramide
and C16:ceramide (34,35). RT-PCR results of this study have
shown for the first time that resveratrol treatment resulted in the
upregulation of LASS2, LASS4, LASS5, and LASS6 genes in a
dose-dependent fashion in human K562 CML cells. There were
significant decreases in the expression levels of GCS and SK-1
genes in response to increasing concentrations of resveratrol in
K562 cells. These results suggest that resveratrol increases in-
tracellular concentrations of ceramides via induction of its de
novo synthesis and also inhibition of the conversion of endoge-
nous apoptotic ceramide to antiapoptotic glucosylceramide and
sphingosine-1-phosphate molecules.
In conclusion, we confirmed the cytotoxic effects of resvera-
trol on K562 cells and showed that there were synergistic apop-
totic effects of the combinations of resveratrol with C8:ceramide
or PDMP or SK-1 inhibitor on K562 CML cells. More impor-
tantly, we have shown for the first time that resveratrol triggers
apoptosis through increasing expression levels of LASS genes
and inhibiting the expression levels of GCS and SK-1 in human
K562 CML cell lines. Taken together, all these results may open
the way toward using resveratrol and ceramides as a novel ther-
apeutic or supportive approach for the management of CML.
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